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ABSTRACT  
Donor-derived coccidioidomycosis has caused unexpected morbidity and mortality in transplant 
recipients. All proven or probable reports of donor-derived coccidioidomycosis to the Disease  
Transmission Advisory Committee (DTAC) between 2005 and August, 2012 were reviewed. Six reports of 
proven or probable coccidioidomycosis were discovered. In 4 of 6, the infection was first detected at 
autopsy in the recipient.  In 2 cases it was first identified in the donor. Twenty-one recipients received 
organs from these 6 donors. Transmission occurred in 43% at a median of 30 days post-transplant with a 
mortality rate of 28.5%. Eleven recipients received pre-emptive antifungals, 7 did not receive treatment, 
and treatment information was not reported for 3 recipients. Five of 7 who did not receive 
prophylaxis/treatment expired and all 11 who received early therapy survived. Six deaths occurred 14 to 
55 days after transplant; median of 21 days. For exposed recipients, donor-derived coccidioidomycosis is 
a significant cause of morbidity and mortality. Evidence of infection in one recipient should prompt 
immediate evaluation for treatment of all other recipients from the same donor as preemptive 
treatment was effective. Further studies are needed to decide whether all donors from endemic areas 
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Introduction  
When recognized in the donor and not treated in recipients, donor-derived coccidioidomycosis 
has been a significant cause of unexpected morbidity and mortality after organ transplantation, and fatal 
outcomes have been reported [1-7]. In the US most cases involve donors from Organ Procurement and 
Transplantation (OPTN) region 5, an area that includes New Mexico, Arizona, Utah, Nevada, and 
California. The optimal management and the efficacy of preventative antifungal treatment for exposed 
recipients are not well defined. The purpose of this study was to review all the cases of potential 
transmission of coccidioidomycosis reported to the Disease Transmission Advisory Committee (DTAC) 
and examine possible strategies to prevent donor-derived coccidioidomycosis.  
  
Materials and Methods   
All reports of potential donor-derived transmission events (PDDTEs) to DTAC between January 
2005 and August 2012 were searched for coccidioidomycosis. Coccidioidomycosis was diagnosed based 
on any positive serology test, positive pathology or positive culture for Coccidioides immitis/posadasii in 
donors and/or recipients. The definition of donor-derived infection was based on the previously 
published DTAC categories related to donor derivation and include proven, probable, possible, unlikely, 
intervention without documented transmission, and excluded [8, 9]. Only PDDTEs classified as proven or 
probable as determined by review of DTAC were analyzed. DTAC collects information under confidential 
medical peer review, and thus demographic and clinical information was summarized to prevent 
recognition of a particular case or a particular institution.  
A Pubmed and Medline search of English language journals from 1950-2013 was performed to 
find case reports of donor-derived coccidioidomycosis. The search keywords included Coccidioides 
immitis/posadasii, Coccidioides Species, Coccidioidomycosis, Valley fever, transmission, solid organ 
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Results  
Between January 2005 and August 2012, DTAC investigated 14 donors implicated in PDDTEs for 
transmission of coccidioidomycosis; 6 (43%) were classified as proven (n=5) or probable (n=1) 
transmissions from donors to at least one recipient. Of the 6 coccidioidomycosis donor transmissions, 4 
were first diagnosed in a recipient at the time of autopsy and the remaining 2 cases were first detected 
in the donor after the transplant operation. Coccidioidomycosis transmission occurred in 9 (43%) of 21 
exposed organ recipients (including the 4 fatal index recipient cases) at a median of 30 days (range 6-64) 
after the transplant operation, and 6 (67%) of 9 recipients developed fungal dissemination to multiple 
organs. The mortality at four months follow up after transplantation was 6/21 (28.5%) exposed 
recipients; none of the 11 exposed recipients who received preventative or early treatment died (Figure 
1).  The 6 deaths occurred at a median of 21 days after transplantation (range 14-55). Five of the 6 
donors with proven or probable transmission were from OPTN region 5 (endemic area) and 11 of 14 
PDDTE donors reviewed were also from OPTN region 5.   
Our review of the literature identified 7 donors of organs that were placed in 18 organ recipients 
resulting in 11 (61%) recipients with donor-derived coccidioidomycosis (Table 1). Several of these cases 
occurred outside the US and others in the US before 2008 (our first DTAC case occurred in 2008), none 
of these would be duplicated by the DTAC series. Of the recipients with known information, 40% were 
female, and median age was 46 years (range 18-66). Donor-derived coccidioidomycosis was recognized 
at a median of 14 (range 6-60) days after transplantation. The overall mortality was 44.4% (8/18) with 
86% (7/8) of these deaths directly attributable to coccidioidomycosis; all 7 deaths had evidence of 
disseminated coccidioidomycosis to multiple organs (n=6) or the central nervous system (n=1). In the 
seven deaths, transmission and dissemination occurred after kidney alone (n=3), simultaneous kidney 
and pancreas (n=1), Kidney-liver (n=1), heart (n=1), and bilateral lung transplantation (n=1). Five of the 7 
(71%) donors had been living in or had visited endemic areas for coccidioidomycosis. One donor was 
from France, but visited Arizona two months before becoming a donor to a single lung transplant 
recipient (case 6 in the table). Three donors had evidence of active infection at procurement of organs, 
two with dissemination to central nervous system with meningitis (case 1 and 2 in the table) and one 
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Discussion  
The use of organ donors from areas endemic for coccidioidomycosis may lead to transmission of this 
fungal pathogen to organ recipients as illustrated in the published literature and the DTAC experience 
presented here [1-7] . Donors may have active infection not recognized at their evaluation for organ 
donation or may have prior infection with contained but viable organisms that reactivate in the setting 
of recipient immunosuppression. In one series, seropositivity of potential kidney and liver donors in an 
endemic area was 2.1% [10].  Also, a living donor may be incubating coccidioidomycosis at the time of 
evaluation with no symptoms and negative serology but later develop symptoms and become 
seropositive [10]. As our report illustrates, for exposed recipients the risk of significant morbidity and 
mortality is high, and poor outcomes typically occur soon after transplantation allowing little time for 
diagnosis and treatment once symptoms occur. Our data suggest, however, that preventative treatment 
with anti-fungal drugs of exposed individuals is very effective in preventing disseminated disease and 
death compared to those exposed recipients who were not treated. Thus, we believe that evidence of 
coccidioidomycosis infection in one recipient should prompt initiation of treatment in all other recipients 
preemptively. Similarly, if serologic or other evidence of coccidioidomycosis in the donor becomes 
available after transplant, we also recommend evaluation of the need for treatment of all recipients of 
organs from this donor.    
Our data do not address the appropriate duration, dose, or drug that should be used as part of 
preventative therapy.  The American Society of Transplantation’s Infectious Disease Community of 
Practice provides some expert opinion regarding these questions [11]. The guidelines recommend that 
recipients of an organ from a donor with pulmonary coccidioidomycosis should receive fluconazole 400 
mg daily for 3- 12 months if non-lung organ recipient with an option of lifelong therapy at 200 mg daily 
after the first year. For lung recipients of organs from donors with pulmonary coccidioidomycosis, the 
recommendation is lifelong fluconazole, 400 mg daily. All recipients of donors with evidence of 
extrapulmonary coccidioidomycosis should receive lifelong fluconazole 400 mg daily, with careful 
laboratory, clinical, and radiological follow up if prophylaxis is discontinued. If a donor is seropositive 
without a documented focus of infection, the lung recipient should receive 400 mg of fluconazole daily 
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  An important issue is the potential role of universal or targeted serological donor screening in 
endemic regions in order to identify donors at risk of transmitting coccidioidomycosis. Information 
regarding endemicity of coccidioidomycosis was obtained by skin test [12]. In the United States, OPTN 
region 5 (California, Arizona, Nevada, Utah, New Mexico) and Southern Texas is the primary geographic 
region endemic for coccidioidomycosis.  Within this region, parts of Arizona and California are at a 
particularly high risk (example, Sonoran desert in Arizona, and San Joaquin valley in California) [13, 14]. 
Because of the risk of “imported” cases, clinicians should also be aware of the epidemiology outside the 
US [12]. Countries with endemic areas include Mexico, Guatemala, Honduras and other countries in 
South and Central America [12]. The predictably elevated risk for prior infection with coccidioidomycosis 
within endemic region suggests that recipients of organs from donors who live in Region 5 might benefit 
from targeted serologic screening of donors. This recommendation might be extended to potential 
donors who visited or lived in the past in Region 5 but were not residing there at the time of donation.  
While clearly cases of donor-derived transmission of coccidioidomycosis have occurred from such 
donors, the lack of data to differentiate what might be a “high risk” exposure for donors with a history of 
travel to an endemic region would suggest that screening donors for any transient travel to a high risk 
region would not likely be cost-effective nor could not it be reliably implemented. Further st udies are 
needed to determine whether all donors in endemic areas (e.g. OPTN region 5) should have routine 
coccidioidomycosis serology testing. In the absence of such data, it is worth noting that one of the 
authors of this report who works in an endemic area for coccidioidomycosis uses routine prophylaxis for 
coccidioidomycosis in all organ recipients for 12 months together with serological screening of all donors 
and recipients. Seronegative organ recipients are usually rechecked yearly, or if there is a clinical 
indication.  This center is currently using universal prophylaxis because of failure of targeted prophylaxis 
with diagnosis of new cases of coccidioidomycosis within one year after transplantation [15]
The OPTN/DTAC has published guidance regarding testing of potential living donors for seasonal and 
endemic infections [16]. A consideration for coccidioidomycosis screening include those who reside or 
stayed in endemic areas, those with symptoms or signs of active infection and those with history of 
coccidioidomycosis [16]. Implementation of epidemiologic risk based screening will not likely eliminate 
all cases of donor derived coccidioidomycosis in the United States. It is unrealistic to believe that Organ 
Procurement Organizations would be able to get a reliable travel history on all potential donors.  
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the US. Recently three non-transplant cases of coccidioidomycosis reported from Washington State had 
no history of residence or travel to endemic area [17]. Soil was sampled and investigated by the CDC’s 
Mycotic Disease Laboratory by PCR. C. immitis/posadasii was found in 6 of 22 soil samples, and viable 
fungus was isolated in 4 samples [18]. This shows that coccidioidomycosis may be found outside the 
known endemic areas, although currently the major risk area remains the Southwestern United States.   
This study has a number of important limitations. In some cases the information was incomplete; 
furthermore, the diagnostic methods and treatments varied between treating medical centers. The 
DTAC reporting system is required but passive, and all cases of donor-derived coccidioidomycosis or 
donor infection with coccidioidomycosis may not have been reported. Thus, we are not able to reliably 
assess the risk faced by a recipient of an infected donor, especially one with latent infection. As DTAC 
reports are collected under confidential peer review, information is reported in aggregate. Thus no 
attempt was made to compare our information and the information obtained from review of the 
literature. We cannot confirm or exclude the possibility of duplication between DTAC records and cases 
reported in the literature during the same time period.  Nevertheless, viewing these confirmed donor 
derived cases in the aggregate provides a useful alert for transplant professionals who may not be fully 
aware of this risk
In summary, data from the review of the DTAC experience and the literature demonstrate that 
donor-derived coccidioidomycosis can be life threatening and typically occurs soon after transplantation. 
Preventative antifungal treatment, however, may be life-saving if administered to exposed recipients. 
Efficient communication between OPOs and transplant centers is critical to this process. While our data 
does not specifically address the value of universal or targeted donor testing in endemic areas (or those 
with previous residence in endemic areas), the lethality of donor-derived coccidioidomycosis combined 
with the availability of effective preventative therapy emphasizes the need for a careful evaluation of 
the potential benefit of such a practice. Clinically appropriate screening and prophylaxis are crucial to 
prevent coccidioidomycosis in endemic areas where there is potential constant exposure. 
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Figure Legends  
Figure 1: Outcome of recipients exposed to coccidioidomycosis  
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 Case  Donor 
Demog  





or early treatment  
Outcome  Cocci Death/Outcome  Comment  
1 [1]   52F, 
AfAm  
Had been living in Los Angeles, 
confusion, abnormal CSF, abnormal 
brain MRI with hydrocephalus, 
serum CF is 1:4, liver bx at 
procurement with granulomas  
1  heart  66M  His  no  Ill day 16, died  Yes, diss multiple organs  Donor at time procurement 
with cocci meningitis  2  2nd 40M   kidney  AfAm  no  Ill day 13, died  Yes, diss multiple organs, also 
kidney sbscess  
3  Kidney-liver, 
previous  
living liv  
23M  His  No but treated D14 
vori, then ampho B, 
then flu  
Ill day 14, Survived, 
liver bx granulomas 
and spherules  
Diss to liver, lung, blood, CF at 3 
months is 1:64  
2 [2]   36M,  
AfAm  
Presented with headaches, had 
cocci meningitis, CF was 1:32. 
Previous treated diss cocci in AZ  
1  liver  46M  W  No, treated D14  flu, 
then ampho B  
Ill day 13, died  Yes, diss to multiple organs, 
including liver  
Donor in AZ 1995-2000 and 
diagnosed with disseminated 
cocci in 1996 to skin and bone  2  kidney  28M  AfAm  No, treat D19 flu  Ill day 11, died  Yes, diss to multiple organs 
including kidney, pre-Tx CF was 
negative  
3  kidney  58F  AfAm  No but given itra 200 




3 [3]   22M  
AfAm  
Immigrated to the US from Jamaica 
in 2001to non-endemic area  
1  kidney  19M  AfAm  No but treated D30 
vori, then liposomal 
ampho B, then flu  
Ill day 29, survived  Pos cocci in lung and blood, serology 
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2  Kidney 
pancreas  
45F  W  No, micafung D35  Ill day 26, died  Yes, diss lung and blood  
3  liver  63F  W  Yes flu, and  D35 on  
fluc  
survived  Ill day 51, developed bil  lung 
nodules, negative serology  
4  Bil lung  62F  W  Yes, vori  survived  Day 53 serology CF 1:2  
5  heart  18M  AfAm  No, D53 flu  died  No, sudden cardiac death, CF day 56 
negative  
4 [4]   F  Resided in AZ, hilar lymph node 
was positive for cocci, he liked to 
hike  
1  Bil lung;   21M  W  No but treated, D6  
flu  
Ill day 6, survived    1-cm firm level 4 hilar lymph 
node found at organ harvest 
positive for cocci  
5 [5]  30  Resident of non-endemic area, 
visited Mexico 2 years earlier  
1  Bil lung  61    no  Ill first week, died  Yes, diss multiple organs    
6 [6]     France resident, visited AZ few 
months before donation  
1  Single lung  58M  France  Yes, itra  survived  Yes, diss multiple organs, also 
kidney sbscess  
  
7 [7]   38/F  Not known  1  Kidney  62M  Portugal  no  died  Diss to liver, lung, blood, CF at 3 
months is 1:64  
No travel history was obtained 
on donor and no pretx serology 
was obtained  2  2nd     kidney  Portugal  no  survived  Yes, diss to multiple organs, 
including liver  
3  Liver    Portugal  no  survived  Yes, diss to multiple organs 
including kidney, pre-Tx CF was 
negative  
4  Heart    Portugal  no  survived    
  
Table 1: Published cases of donor-derived coccidioidomycosis and outcome   
Pos=positive, AfAm=African American, M=male, F=female, Demo=Demographics, Recip=recipient, Bil=bilateral, His=Hispanic, W=white,  
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